Termination Letter for Consulting Agreement between Civitas Therapeutics, Inc. and Robert Roche

Summary

Civitas Therapeutics, Inc. and Robert Roche agree to terminate their Consulting Agreement, originally dated December 16, 2011 and amended January 1, 2013, effective immediately before the company's initial public offering. After termination, Robert Roche will continue to serve on the Board of Directors and will be compensated according to the company's non-employee director compensation policies. Certain sections of the original Consulting Agreement will remain in effect. This termination does not affect Roche's board membership.

EX-10.22 28 d719498dex1022.htm EX-10.22 EX-10.22

Exhibit 10.22

Civitas Therapeutics, Inc.

September 12, 2014

Dear Bob:

This letter confirms the termination of the Consulting Agreement dated December 16, 2011, as amended January 1, 2013 (the “Consulting Agreement”), regarding your service as a member of the Board of Directors (the “Board”) of Civitas Therapeutics, Inc. (the “Company”). Accordingly, pursuant to Section 7.3(b) of the Consulting Agreement and effective as of the day immediately preceding the day on which the initial public offering of the Company’s common stock is consummated, the Company hereby terminates the Consulting Agreement and, by signing below, you hereby acknowledge and agree to such termination of the Consulting Agreement. Upon termination of the Consulting Agreement, you shall be entitled to compensation as a member of the Board pursuant to the Company’s non-employee director compensation policies, as in effect from time to time. For the avoidance of doubt, the terms of sections 1, 5, 6 and 8 of the Consulting Agreement shall survive its termination and the termination of the Consulting Agreement will not terminate your service as a member of the Board.

 

Sincerely,

Civitas Therapeutics, Inc.

  /s/ Mark Iwicki

Name:

  Mark Iwicki

Title:

  President and Chief Executive Officer

 

Acknowledged and Agreed
  /s/ Robert Roche
Robert Roche